Oncimmune

Oncimmune is an immunodiagnostics developer that focuses on immuno-oncology, autoimmune diseases, and infectious diseases. The company was founded in 2002 as a spin-out from the University of Nottingham to commercialize a blood test for the early detection of cancer. In 2023, Oncimmune sold its early cancer detection business, including the EarlyCDT Lung test, to Freenome Holdings, Inc., and now focuses on its ImmunoINSIGHTS service business.

The company's core service, ImmunoINSIGHTS, is a biomarker discovery platform offered to life science organizations. This service utilizes a proprietary library of over 9,000 immunogenic proteins to profile autoantibodies in patient samples. This helps pharmaceutical and biotechnology partners to optimize drug development by stratifying patients, identifying biomarkers for therapeutic response, and understanding disease mechanisms, which can lead to more targeted and safer treatments. The business model is primarily fee-for-service, working with seven of the top fifteen global pharmaceutical companies, and it is also exploring strategic partnerships involving royalties and co-development projects.

The ImmunoINSIGHTS platform leverages Luminex xMAP® multiplex technology to analyze small sample volumes for high-throughput autoantibody profiling. This technology is instrumental in various stages of clinical trials, from confirming a drug's mechanism of action to predicting immune-related adverse events. Recent technological breakthroughs include the ability to reliably profile Immunoglobulin E (IgE) autoantibodies, opening new research and commercial avenues. The company has its main discovery research center in Dortmund, Germany, and a commercial office in Boston, MA, USA. The current leadership team includes Martin Gouldstone as CEO and Martin Hudson as CFO.

Keywords: immunodiagnostics, autoantibody profiling, biomarker discovery, precision medicine, immuno-oncology, autoimmune disease, ImmunoINSIGHTS, drug development, life sciences, clinical trials